Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution

Similar Items

• Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR‐G719A and Other Uncommon EGFR Mutations
  od: Sehgal, Kartik, i dr.
  Izdano: (2020)
• Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
  od: Watanabe, Satoshi, i dr.
  Izdano: (2014)
• Long-term Survival With Afatinib in a Patient With Lung Adenocarcinoma Harboring Double Uncommon EGFR L861Q and G719X Mutations
  od: OHARA, GEN, i dr.
  Izdano: (2020)
• Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report
  od: Cai, Yangyang, i dr.
  Izdano: (2020)
• Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
  od: LI, JING, i dr.
  Izdano: (2013)